The Drug Enforcement Administration (DEA) is scheduled to hold a hearing later this month to consider the broader federal rescheduling of cannabis. The move follows U.S. Attorney...
The federal decision to reclassify medical marijuana to Schedule III offers tax benefits and research opportunities for cannabis businesses, but states face regulatory uncertainty as federal...
